Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Genvoya then Epclusa then Biktarvy in HIV-HCV Co-infected Patients on OST
NCT03549312Phase 4Unknown
- Sponsor
- Saskatchewan Health Authority
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of tenofovir alafenamide, velpatasvir, bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), hepatitis C (HCV), sponsored by Saskatchewan Health Authority. Status: unknown.
02
Drugs
tenofovir alafenamidevelpatasvirbictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03549312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549312.